Continuous values are presented as median (interquartile range) and categorical ones as n (%). COVID-19, coronavirus disease 2019; IQR, interquartile range.

estimated using Kaplan-Meier method and compared using the logrank test. Results: Of the 86 patients included (median age (IQR) 59 years (46-67), 69% male gender, median time from transplantation 6.9 years (3.0-15.2)) 77% required hospitalization including 39% in ICU. Twenty patients died (CFR: 23%). No difference in 3-month survival was observed between 2020 and 2019 recipient cohorts (98.8% [98.5%-99.1%] versus 99.0% [98.7%-99.2%], respectively) (Figure 2). Conclusion: While COVID-19 was associated with high fatality rate in heart transplant recipients, we could not identify an excess mortality in 2020 heart recipient cohort. These findings suggest that continuing heart transplant activity during the COVID-19 pandemic was a reasonable option.

No abstract

central regurgitant jet and holodiastolic flow reversal in the pulmonary arteries. The patient underwent a tricuspid repair with a 30mm tricuspid ring and pulmonic valve replacement with a 25 mm bovine valve on POD 10. Surgical endomyocardial biopsy had no evidence of rejection. His heart failure symptoms resolved and he was discharged 4 weeks post op. Summary: We describe a novel case of a 39 yo orthotopic heart transplant recipient with acute post operative concomitant TR and PI with right heart failure requiring a tricuspid ring annuloplasty and pulmonic valve replacement. To date, there are no such reported complications after heart transplant. The incidence of isolated tricuspid valve regurgitation after heart transplant have decreased with the bicaval transplantation technique however not eliminated. Literature suggests that isolated moderate to severe tricuspid valve regurgitation should under a repair or replacement early post transplantation. Pulmonic valve insufficiency is extremely rare after heart transplant and management strategies are not well defined.

No abstract